(Press-News.org) Embargoed for release until 5:00 p.m. ET on Monday 2 June 2025
Follow @Annalsofim on X, Facebook, Instagram, threads, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------
Cognitive outcomes similar after noncardiac surgery whether perioperative hypotension- or hypertension-avoidance strategies employed
Abstract: https://www.acpjournals.org/doi/10.7326/ANNALS-24-02841
Editorial: https://www.acpjournals.org/doi/10.7326/ANNALS-25-01409
URL goes live when the embargo lifts
A randomized controlled trial compared the effect of hypotension-avoidance versus hypertension-avoidance strategies on delirium and one-year cognitive decline after non-cardiac surgery. The study found no differences in neurocognitive outcomes between the two perioperative blood pressure strategies, further emphasizing previous research that found a lack of difference in clinically important outcomes between these two strategies. According to the researchers, this is the largest existing trial evaluating interventions targeting neurocognitive outcomes after noncardiac surgery. The study is published in Annals of Internal Medicine.
McMaster University/Population Health Research Institute, Humanitas University, and colleagues studied 2,603 high-vascular-risk adult patients who had major noncardiac surgery at 54 centers in 19 countries. The researchers aimed to compare the effects on postoperative delirium and one-year cognitive decline of two blood pressure management strategies that differ in intraoperative mean arterial pressure (MAP) targets and in perioperative management of chronic antihypertensive medications. Patients were randomized to either a hypotension-avoidance strategy (intraoperative MAP target ≥80 mm Hg; chronic renin–angiotensin system inhibitors [RASI] withheld perioperatively, and other chronic antihypertensive medications continued based on patient blood pressure) or a hypertension-avoidance strategy (intraoperative MAP target ≥60 mm Hg; all chronic antihypertensive medications continued perioperatively) and were screened for delirium twice daily from the first day after surgery until postoperative day three, discharge or delirium diagnosis, whichever came first, using a three-minute diagnostic interview. 1,001 patients were enrolled in the one-year cognitive decline evaluation. The researchers found that delirium occurred in 7.3% of patients in the hypotension-avoidance group and 7% of patients in the hypertension-avoidance group. The median delirium severity score among patients with delirium was 4.0 in both groups. A similar proportion of patients in the two groups had cognitive decline one year after surgery. The findings do not support targeting an intraoperative MAP ≥80 mm Hg, compared with a MAP ≥60 mm Hg, and withholding RASI and continuing other chronic antihypertensive medications following an algorithm, compared with continuing all chronic antihypertensive medications, to improve postoperative neurocognitive outcomes.
Media contacts: For an embargoed PDF, please contact Angela Collom at acollom@acponline.org. To contact corresponding author Maura Marcucci, MD, please email Adam Ward at warda17@mcmaster.ca or Francesca Barocco at francesca.barocco@humanitas.it.
----------------------------
Also new this issue:
The Doctors Made the Difference
Katherine C. McKenzie, MD
Ideas and Opinions
Abstract: https://www.acpjournals.org/doi/10.7326/ANNALS-24-02841
A Call for Compassion for People Facing Lung Cancer: The American Cancer Society National Lung Cancer Roundtable
Jamie L. Studts, PhD, et al.
Ideas and Opinions
Abstract: https://www.acpjournals.org/doi/10.7326/ANNALS-24-03167
END
Cognitive outcomes similar after noncardiac surgery whether perioperative hypotension- or hypertension-avoidance strategies employed
2025-06-02
ELSE PRESS RELEASES FROM THIS DATE:
Research spotlight: regional disparities in opioid overdose mortality persist despite national decline
2025-06-02
Sarah Wakeman, MD, Senior Medical Director for Substance Use Disorder at Mass General Brigham, is the co-senior author and Will Oles, BS, of Harvard Medical School, is a corresponding author of a paper published in the Journal of General Internal Medicine, “Geographic Trends in Opioid and Polysubstance Overdose Deaths in the US, 2014-2023.”
Q: How would you summarize your study for a lay audience?
In May 2024, the Centers for Disease Control (CDC) announced a national decline in the ...
Fighting myeloma with fiber: Plant-based diet offers promise
2025-06-02
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.
Multiple myeloma is often preceded by early, non-cancerous conditions involving abnormal plasma cells, a type of white blood cell found in the bone marrow. Having a high body weight, ...
What makes someone leave a Medicare Advantage plan?
2025-06-02
More than half of older Americans now get their Medicare coverage through an insurance company’s Medicare Advantage plan. But many go on to switch plans or even leave for traditional Medicare when Open Enrollment comes around each autumn.
Researchers have had a hard time getting access to data that could help them understand what drives these changes, which have major implications for federal spending on Medicare as well as individuals’ health.
Now, a new study in the June issue of Health Affairs peels back the curtain on what motivates people to switch ...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
2025-06-02
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes.
First-in-class antibody-drug conjugate, pivekimab sunirine (PVEK), was safe and effective.
PVEK achieved an overall response rate of 85% and complete response rate of 70% as frontline treatment in newly diagnosed patients with BPDCN.
Findings suggest this treatment should be considered as a new standard of care for these patients.
ABSTRACT: 6502
CHICAGO, JUNE 2, 2025 ― The first-in-class ...
Advancing personalized medicine through pharmacogenomics: Insights from Ochsner Health
2025-06-02
In a report recently published in the American Journal of Health-System Pharmacy, the Ochsner Health system delves into the multifaceted implementation of pharmacogenomics—a rapidly evolving field that examines how genetics influence individual responses to medication. This comprehensive article, led by Dr. Catherine Oliver and a team of experts in pharmacy services, provides an insightful blueprint for health systems aiming to integrate pharmacogenomics into clinical practice.
"Pharmacogenomics embodies a new frontier in precision medicine, enabling us to fine-tune treatments ...
Researchers tested an asthma drug for treating alcoholism. It failed except with this group
2025-06-02
Key takeaways
Ibudilast is a drug approved in Japan for the treatment of asthma and post-stroke dizziness by targeting inflammation; previous research suggested it could also help people reduce their drinking.
A UCLA clinical trial, however, has now shown that ibudilast worked no better than a placebo for trial participants in reducing alcohol consumption, although it did have a positive effect on women.
Women tend to have higher levels of inflammation than men, and the results of ibudilast testing with women point toward ...
Set it and forget it: Autonomous structures can be programmed to jump days in advance
2025-06-02
Researchers have created dynamic structures that leap into the air on a predetermined schedule without intervention from computers or external stimuli. Precisely when these “metashells” jump, and how high they jump, is engineered into the physical structure of the materials.
“There are structures that ‘jump’ immediately when loading is removed – such as when a coiled spring is released,” says Jie Yin, corresponding author of a paper on the work and an associate professor of mechanical engineering at North Carolina State University. “We wanted to create a structure that does not rely on external stimuli and allows us to dictate the timing ...
Iron from coal, steel industries alters North Pacific ecosystem
2025-06-02
Along with nutrients like nitrogen and phosphorus, iron is essential for the growth of microscopic phytoplankton in the ocean. However, a new study led by oceanographers at the University of Hawai‘i (UH) at Mānoa revealed that iron released from industrial processes, such as coal combustion and steel making, is altering the ecosystem in the North Pacific Transition Zone, a region just north of Hawai‘i that is important for fisheries in the Pacific. The study was published today in the Proceedings of the National Academy of Sciences USA.
“This ...
Canadian researcher receives funding from ARIA to unlock potential of plants
2025-06-02
Imagine a world where crops can thrive regardless of climate or disease and provide all the essential nutrients our bodies need. Researchers at Western University’s Schulich School of Medicine & Dentistry are now part of a U.K.-based initiative to explore that very possibility.
The Advanced Research + Invention Agency (ARIA), the U.K.’s research and development funding agency, announced June 2 that Schulich Medicine & Dentistry professor Bogumil Karas has been named ...
Visionary support from Veale Foundation will establish university hospitals Veale Healthcare Transformation Institute
2025-06-02
CLEVELAND – A new visionary gift from the Veale Foundation will establish the University Hospitals Veale Healthcare Transformation Institute. The $23.5 million in support represents an investment in University Hospitals’ value-based care initiatives. Peter J. Pronovost, MD, PhD, UH Chief Quality and Clinical Transformation Officer, will serve as the institute’s founding and first president.
“Healthcare today tells a story of scarcity – it harms too often, costs too much and learns and ...